CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Multiomic Preclinical Models to Define the...

Mitch Sanders, Chief Scientific Officer and EVP of...

Data Connectivity and Collaboration in...

David Bang, Global Vice President Strategic...

Managing Impacts of Technology...

Olga Minkov, Executive Director, Operations -...

Clinical Trial Analytics Prescription for...

Ankit Lodha, Associate Director, Clinical Analytics...

De-risking the Preclinical Phase of...

Ralph Gareus, Director Business Development, The...

The Value of New Antibiotics in the Fight...

Piero Rijli, Corporate Director, Regulatory...

Improving Minimal Residual Disease...

Steven Henck, Ph.D., Vice President of R&D,...

Developing Patient-Centric Precision...

Sanjay Konagurthu, Senior Director, PDS Global...

Multiomic Preclinical Models to Define the...

Mitch Sanders, Chief Scientific Officer and EVP of...

Data Connectivity and Collaboration in...

David Bang, Global Vice President Strategic...

Managing Impacts of Technology...

Olga Minkov, Executive Director, Operations -...

Clinical Trial Analytics Prescription for...

Ankit Lodha, Associate Director, Clinical Analytics...

De-risking the Preclinical Phase of...

Ralph Gareus, Director Business Development, The...

The Value of New Antibiotics in the Fight...

Piero Rijli, Corporate Director, Regulatory...

Improving Minimal Residual Disease...

Steven Henck, Ph.D., Vice President of R&D,...

Developing Patient-Centric Precision...

Sanjay Konagurthu, Senior Director, PDS Global...

Driving Digital Transformation in the Pharma Industry

Wayne Hull, Chief Digital & Technology Officer, PCI Pharma Services
Tweet

The healthcare industry is highly regulated and as a result, has been slow to change and embrace new technology. At PCI, a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, we see ourselves as pioneers who are challenging the status quo. We are looking ahead to the future and see the huge potential that digitization holds for the pharmaceutical supply chain. We are now a year into a three-year corporate digital transformation strategy and have made great progress. Below are some of the factors contributing to our early success:


• Listen and Learn: We’ve taken a novel approach to forming our strategy by listening to what our clients want, and using this feedback to guide the path forward. Through a number of client conversations and workshops, we’ve identified important areas of focus. Given our shared purpose to bring life-changing therapies to patients faster, our clients were more than willing to engage with us in this way.


• Set Focused Goals and a Roadmap to Get There: To meet the future needs of our global client base, we established three very clear objectives. They are: enhance customer experiences, digitize core business processes to achieve collaboration and efficiencies, and align IT capabilities for scale. The goals are based on extensive research around the pharmaceutical supply chain industry and digital trends. We also implemented an innovative internal design-thinking process to stimulate ideas from our teams for specific “value initiatives” that would ladder back to these goals. A few examples of these initiatives include a new digital client platform, business process digitization, and electronic quality management.


• Invest in Technologies and Talent: When our CEO Salim Haffar joined PCI in September 2018, he saw an opportunity to take a progressive approach to the way we work and create an industry-leading client experience through digitization. 


His vision was to invest in both talent and emerging technologies to improve our core business operations and create even more value for clients. While technologies like cloud, cyber security, big data, digital[1]marketing and robotics are key to the changes we want to make, seasoned talent to implement these changes is just as critical. As such, we have made new hires and brought the marketing, digital and technology functions closer together, reporting under one structure and working across traditional silos.


Change is never easy, especially in a conservative industry. Employees and clients alike need to be supported to adopt new systems and technologies


• Encourage Clients and Employees to Embrace Change: Change is never easy, especially in a conservative industry. Employees and clients alike need to be supported to adopt new systems and technologies. There needs to a top-down approach with clear and transparent communications about the strategy so stakeholders understand the bigger picture and the benefits they will ultimately realize. Leadership needs to layout what employees can expect in the future and how the organization will support them with training for new software, platforms, etc. Likewise, the organization needs to be prepared to train clients and may need to take a phased approach so it’s manageable.


As we continue in our digital transformation journey at PCI, we are building evidence that our investments are providing real and measurable returns. As a result, we are more confident to leverage new innovations and implement emerging technologies sooner. This is an exciting process and our ability to evolve quickly and propose even more novel solutions is what will continue to differentiate PCI in this industry.


Weekly Brief

loading
Top 20 Clinical-Stage Biopharmaceutical Companies - 2022
> <
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue

Read Also

The Value of New Antibiotics in the Fight Against AMR

Piero Rijli, Corporate Director, Regulatory Activities and Market Access, MENARINI Group

Improving Minimal Residual Disease Detection Using NGS

Steven Henck, Ph.D., Vice President of R&D, Integrated DNA Technologies

Multiomic Preclinical Models to Define the Mechanism of Action

Mitch Sanders, Chief Scientific Officer and EVP of the ProDevLab, at Alira Health

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Sanjay Konagurthu, Senior Director, PDS Global Science and Technology, Thermo Fisher Scientific

What the New EMA Draft "Guideline on Computerised Systems and Electronic Data" Means to Your Systems

Cathlin Shapiro, Director, Technology Quality Assurance, Parexel

Pharmaceutical Tablet Coating - Past, Present and Future

Steve Brown, Senior Director EU and APAC Global Manufacturing Science and Technology, Teva Pharmaceuticals [NYSE: TEVA]

Dynamic Commercial Aspects of Life Sciences

Jim Cooper, Director, Clinical Operations, Moderna

Achieving trial master file quality, timeliness and completeness

Susan K. Maue, Designation : Managing Director PharmaLex
Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://clinical-stage-biopharmaceutical.lifesciencesreview.com/cxoinsight/driving-digital-transformation-in-the-pharma-industry-nwid-771.html